Neurotez

About the offering

INTRODUCTION From the CEO “I have personal experience on how devastating a brain disorder that changes your behavior and personality can be. My mother, who died in 2014, suffered from Alzheimer’s. My personal commitment is to develop a cure for Alzheimer’s disease, no matter what this may cost. There is no plan B.” - Nikolaos Tezapsidis CEO, Neurotez PROBLEM Alzheimer’s disease affects about 6 million Americans and 50 million patients worldwide. Current medications provide limited relief. Many of our competitors are focusing on removing either Abeta or tau deposits from the brain where they form plaques and tangles. None of these efforts have generated any effective drug for the last 18 years since the first anti-Abeta trial started. The idea that Abeta and plaque do not cause Alzheimer’s is gaining momentum in the research community; we were determined to look for a different solution prior to the formation of the plaques. SOLUTION Our novel approach focuses on Leptin, a naturally occurring human hormone associated with various metabolic effects, which has a large number of receptors in memory centers of the brain. Hippocampus (in red) responsible for memory formation, cognition and executive function is severely affected by the disease. This region is rich in Leptin receptors. This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels. We are developing Memtin™ to treat Leptin deficiency in Alzheimer’s patients. This Leptin product may act as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk. "Alzheimer's Drugs Market Size is projected to reach US$~9.67 billion by 2031." --- Exclusive Report by Growth Plus Reports MARKET Alzheimer's is the fifth-leading cause of death among those aged 65 and older and is also a leading cause of disability and poor health. An estimated 5.8 million Americans aged 65 and older were living with Alzheimer's dementia in 2020. 80% of this population was aged 75 or older. This number is expected to increase to 13.5 million by 2050. Among people of age 70, 61% of those with Alzheimer's dementia are expected to die before the age of 80 compared with 30% of people without Alzheimer's. The rising prevalence of Alzheimer's disease has increased the demand for the treatment, which in turn is expected to boost the market growth. (2020 Alzheimer's disease facts and figures) SUCCESS TO DATE ​​​​​InvestAcure Coin Award 2019 InvestAcure honored Nik Tezapsidis with the Cure Coin Award for his work in the development of Memtin, a novel recombinant human Leptin product, used as a hormone replacement therapy, showing potential in both slowing down and preventing Alzheimer’s. 2010 Incubator Company to Watch Neurotez was chosen as a 2010 Incubator Company to Watch at the NJTC Gala Awards Previous Funding Total = $4.8M: National Institutes of Health IRS Qualifying Therapeutic Discovery Project Grant New Jersey Commission of Science and Technology Previous crowdfunding raise of $300k

FAQ